Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit

Immunotherapy response score (IRS) integrates tumor mutation burden (TMB) and quantitative expression biomarkers to predict anti-PD-1/PD-L1 [PD-(L)1] monotherapy benefit. Here, we evaluated IRS in additional cohorts. Patients from an observational trial (NCT03061305) treated with anti-PD-(L)1 monoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulen, Benjamin J., Khazanov, Nickolay A., Hovelson, Daniel H., Lamb, Laura E., Matrana, Marc, Burkard, Mark E., Yang, Eddy Shih-Hsin, Edenfield, William J., Claire Dees, Elizabeth, Onitilo, Adedayo A., Buchschacher, Gary L., Miller, Alan M., Parsons, Benjamin M., Wassenaar, Timothy R., Suga, Jennifer M., Siegel, Robert D., Irvin, William, Nair, Suresh, Slim, Jennifer N., Misleh, Jamal, Khatri, Jamil, Masters, Gregory A., Thomas, Sachdev, Safa, Malek M., Anderson, Daniel M., Mowers, Jonathan, Dusenbery, Anna C., Drewery, Stephanie, Plouffe, Komal, Reeder, Travis, Vakil, Hana, Patrias, Lynnae, Falzetta, Amanda, Hamilton, Ryan, Kwiatkowski, Kat, Johnson, D. Bryan, Rhodes, Daniel R., Tomlins, Scott A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367935/
https://www.ncbi.nlm.nih.gov/pubmed/37497337
http://dx.doi.org/10.1158/2767-9764.CRC-23-0036

Ejemplares similares

Ejemplares similares